RNAZ (TransCode Therapeutics) Net Income Including Noncontrolling Interests : $-25.51 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is TransCode Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

TransCode Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was $-12.09 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was $-25.51 Mil.

TransCode Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for TransCode Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransCode Therapeutics Net Income Including Noncontrolling Interests Chart

TransCode Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income Including Noncontrolling Interests

Get a 7-Day Free Trial

-2.34

-6.84

-17.57

-18.55

-16.76

TransCode Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income Including Noncontrolling Interests	Get a 7-Day Free Trial															-3.33	-5.19	-2.32	-5.92	-12.09

TransCode Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.51 Mil.

TransCode Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of TransCode Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

TransCode Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » Net Income Including Noncontrolling Interests

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Liberty Square, No. 2382, Boston, MA, USA, 02109

Website

https://www.transcodetherapeutics.com

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Executives

Robert Michael Dudley	director, 10 percent owner, officer: Chief Executive Officer	C/O TRANSCODE THERAPEUTICS, 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Thomas A Fitzgerald	director, officer: VP, Chief Financial Officer	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Philippe Calais	director	C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Anna Moore	10 percent owner	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Zdravka Medarova	10 percent owner	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Erik Manting	director	C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109